Tracking Your ACT Response: Blood Markers and Clinical Assessments | ALIV

A recurring challenge in regenerative medicine is that clinical improvement from ACT often develops more slowly than patients expect — and without objective measurement anchors, the uncertainty of "is it working?" is difficult to manage. ALIV's approach is to establish clear measurement frameworks before each ACT procedure: what markers will be tracked, at what timepoints, and what changes constitute meaningful evidence of biological response. This article explains the measurement approach by condition category.

The Baseline — Before You Start

Objective response assessment is impossible without a documented baseline. At the pre-ACT consultation, ALIV records the relevant clinical measures and blood markers for each patient's condition. These form the reference point against which all subsequent assessments are measured. Patients who bring recent investigation results from another provider also contribute to this baseline — the more complete the baseline picture, the more informative the follow-up assessment at three months.

Inflammatory Conditions (OA, RA, IBD)

Key markers: CRP and ESR (systemic inflammatory activity); IL-6 (where accessible, a more sensitive marker of the inflammatory cytokine environment ACT aims to modulate); and condition-specific markers — RF and anti-CCP for RA, faecal calprotectin for IBD. Clinical assessments: WOMAC pain and function score for OA; DAS28 for RA; Harvey-Bradshaw or Harvey Index for Crohn's. A meaningful response in inflammatory conditions is: CRP reduction of 25% or more; meaningful improvement (clinical significance threshold) in disease activity score. Most inflammatory marker responses are assessable at six to eight weeks — a useful early signal. See: ACT results timeline.

Metabolic Conditions (Diabetes, Liver)

For diabetes: HbA1c at three months (one full HbA1c averaging window); fasting insulin and HOMA-IR for insulin sensitivity; neuropathy symptom scores (standardised tools for peripheral neuropathy severity). For liver: ALT, AST, GGT, bilirubin, and albumin at six to eight weeks and three months; FibroScan or liver elastography at six months if available (measures liver fibrosis progression or regression). A meaningful response: ALT/AST reduction of 20% or more; albumin improvement toward normal range; improved neuropathy score.

Neurological Conditions (Parkinson's, Alzheimer's, SCI)

Neurological response is assessed using standardised clinical rating tools — not blood markers, which are insufficiently sensitive for neurological function change. For Parkinson's: UPDRS (Unified Parkinson's Disease Rating Scale) motor subscale, assessed by the neurologist. For Alzheimer's: MMSE or MoCA (cognitive assessment tools); NPI (neuropsychiatric inventory for non-cognitive symptoms). For SCI: ASIA classification reassessment; motor scoring at the affected segments. These assessments should be conducted by the treating neurologist — ALIV coordinates with the neurologist's assessment schedule to align review points.

What if my blood markers don't improve but I feel better?

Subjective improvement (reduced pain, better energy, improved sleep) is a valid and meaningful clinical outcome — not a second-tier outcome compared to blood markers. In conditions like fibromyalgia and chronic fatigue, subjective improvement with normal blood markers is consistent with the central sensitisation and mitochondrial dysfunction biology that blood markers do not capture. Conversely, blood marker improvement without subjective improvement is also worth documenting — it suggests the biological response is occurring even if the clinical translation is incomplete. Both dimensions together give the most complete picture.

How often should blood markers be checked after ACT?

ALIV's standard follow-up schedule: six to eight weeks post-procedure (early inflammatory marker response); three months (metabolic and broader biological response assessment, also the primary clinical review); six months (consolidation assessment, decision on maintenance or repeat course); twelve months (annual review for patients in a maintenance programme). More frequent monitoring may be appropriate for patients with very active conditions or significant pre-procedure abnormalities.